HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Robert F Siliciano Selected Research

Highly Active Antiretroviral Therapy (HAART)

4/2014A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides.
6/2013Targeting HIV latency: pharmacologic strategies toward eradication.
6/2013From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
2/2013Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.
3/2012Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.
3/2012A quantitative basis for antiretroviral therapy for HIV-1 infection.
1/2011Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.
11/2010Biomarkers of HIV replication.
4/2010Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.
12/2009New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Robert F Siliciano Research Topics

Disease

37Infection
01/2016 - 04/2002
25Viremia
09/2014 - 04/2003
9HIV Infections (HIV Infection)
01/2016 - 02/2002
3Acquired Immunodeficiency Syndrome (AIDS)
01/2012 - 08/2008
2Disease Progression
03/2014 - 06/2013
2Vaccinia
09/2004 - 08/2004
1Hematologic Neoplasms (Hematological Malignancy)
02/2013
1Inflammation
02/2013
1Tuberculosis (Tuberculoses)
01/2012
1Herpes Simplex
12/2009
1Hepatitis B
12/2009
1Chronic Hepatitis B
06/2007
1Pain (Aches)
09/2005

Drug/Important Bio-Agent (IBA)

9RNA (Ribonucleic Acid)IBA
03/2014 - 09/2002
5DNA (Deoxyribonucleic Acid)IBA
01/2016 - 04/2002
5HLA-B57IBA
03/2014 - 05/2006
4Acyclovir (Aciclovir)FDA LinkGeneric
09/2010 - 11/2008
3Proteins (Proteins, Gene)IBA
02/2013 - 03/2008
3EpitopesIBA
01/2011 - 05/2006
3HLA-B Antigens (HLA-B)IBA
02/2010 - 08/2008
2Viral RNAIBA
04/2010 - 02/2005
2entecavirFDA Link
12/2009 - 06/2007
1Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric
06/2015
1Antiviral Agents (Antivirals)IBA
03/2014
1Disulfiram (Antabuse)FDA Link
03/2014
1Histone Deacetylases (Histone Deacetylase)IBA
01/2014
1Histone Deacetylase InhibitorsIBA
01/2014
1Anti-Retroviral Agents (Antiretroviral Agents)IBA
01/2013
1butyl 3-(1H-tetrazol-5-yl)oxanilate (MTB)IBA
01/2012
1Carbon MonoxideIBA
01/2012
1Immunologic Factors (Immunomodulators)IBA
01/2012
1MK 0518FDA Link
07/2011
1IntegrasesIBA
07/2011
1Neutralizing AntibodiesIBA
01/2011
1Minocycline (Cyclops)FDA LinkGeneric
04/2010
1AntigensIBA
02/2010
1AntibodiesIBA
02/2010
1Interleukin-12 (IL 12)IBA
06/2008
1CytokinesIBA
06/2008
1Interleukin-15 (Interleukin 15)IBA
06/2008
1Integrase InhibitorsIBA
03/2008
1Interferon Type IIBA
02/2008
1Valproic Acid (Valproate, Semisodium)FDA LinkGeneric
03/2007
1Immunodominant EpitopesIBA
08/2004
1UbiquitinIBA
08/2004
1Human immunodeficiency virus 1 p16 proteaseIBA
01/2004
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
01/2004

Therapy/Procedure

32Highly Active Antiretroviral Therapy (HAART)
04/2014 - 02/2002
2Art Therapy
01/2016 - 09/2014
1Transplantation (Transplant Recipients)
09/2014
1Withholding Treatment
01/2011
1Aftercare (After-Treatment)
01/2011
1Therapeutics
11/2009